SE ID | SE Region | Sample ID | Tissue type | Biosample name | SE rank | Element | Common SNP | eQTL | Risk SNP | TFBS | CRISPR Cas9 | Gene |
---|---|---|---|---|---|---|---|---|---|---|---|---|
SE_02_066400206 | chr7:117361096-117393772![]() |
Sample_02_0664 | Prostate | LNCaP_DMSO | 206 | 7 | 678 | 20 | 4 | 85 | 243 | ASZ1,WNT2 |
SE_01_006700222 | chr7:117364625-117391722![]() |
Sample_01_0067 | Peritoneal effusion: derived from metastatic site: peritoneal cavity | SUDHL6 | 222 | 4 | 586 | 16 | 4 | 76 | 199 | ASZ1,WNT2 |
SE_02_039700386 | chr7:117374032-117414747![]() |
Sample_02_0397 | Mammary gland | CAL51-MCF-7 | 386 | 8 | 839 | 21 | 7 | 51 | 150 | ASZ1 |
SE_02_107500256 | chr7:117374952-117386225![]() |
Sample_02_1075 | Lymphoma | BC-3 | 256 | 4 | 264 | 6 | 3 | 31 | 150 | ASZ1 |
SE_02_067300643 | chr7:117379783-117387886![]() |
Sample_02_0673 | Prostate | LNCAP_FA | 643 | 2 | 188 | 7 | 2 | 33 | 150 | ASZ1,WNT2 |
SE_02_051100103 | chr7:117381351-117394603![]() |
Sample_02_0511 | Prostate | LNCaP95_shARv7_ETOH | 103 | 3 | 287 | 9 | 2 | 29 | 103 | ASZ1 |
SE_02_050900228 | chr7:117382244-117393272![]() |
Sample_02_0509 | Prostate | LNCaP95_shGFP_ETOH | 228 | 3 | 252 | 8 | 2 | 26 | 92 | ASZ1,WNT2 |
SE_02_051200139 | chr7:117383139-117387390![]() |
Sample_02_0512 | Prostate | LNCaP95_shARv7_DHT | 139 | 4 | 101 | 5 | 2 | 25 | 78 | ASZ1 |
SE_02_149300606 | chr7:117399293-117448491![]() |
Sample_02_1493 | Skin | SK-MEL-5_DMSO_6h | 606 | 9 | 1041 | 26 | 6 | 65 | 195 | ASZ1,CFTR |